Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
Update: 2025-10-30
Description
Eli Lilly's experimental weight-loss pill, orforglipron, has met the FDA's new priority criteria, potentially fast-tracking its review. The drug, which helped patients lose over 12% of their body weight in trials, could be reviewed in just one to two months if approved. Lilly's investment in U.S. manufacturing plants and strong financial quarter, driven by its GLP-1 drugs like Zepbound and Mounjaro, have boosted its position in the growing weight-loss drug market, estimated to be worth $150 billion by the end of the decade. Despite concerns about drug pricing and insurer coverage, Lilly's results have surprised Wall Street and strengthened its GLP-1 drug portfolio.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
